References
- Tramèr MR, Reynolds DJM, Moore RA, McQuay HJ. Impact of covert duplicate publication on meta-analysis: a case study. BMJ 1997;315:635–40
- Melander H, Ahlqvist-Rastad J, Meijer G, Beerman B. Evidence b(i)ased medicine – selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 2003;326:1171–3
- Gøtzsche PC. Multiple publication of reports of drug trials. Eur J Clin Pharmacol 1989;36:429–32
- Jefferson TO. Redundant publication in biomedical sciences: scientific misconduct or necessity? Sci Eng Ethics 1998;4:135–40
- Waldron T. Is duplicate publishing on the increase? BMJ 1992;304:1029
- International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. www.icmje.org [accessed 23 Sept 2003]
- Chalmers I. Underreporting research is scientific misconduct. J Am Med Assoc 1990;263:1405–8
- Tonks A. A clinical trial register for Europe. Stop talking and start making it happen. BMJ 2003;325:1314–15
- Wager E, Field EA, Grossman L. Good Publication Practice for pharmaceutical companies. Curr Med Res Opin 2003;19:149–54
- McNamee D. Review of clinical protocols at the Lancet. Lancet 2001;357:1819–20
- BioMed Central Instructions to authors. http://www.biomedcentral.com/bmccancer/ifora/ [accessed 23 Sept 2003]
- Gibbs TG, Wager E. Realities of trial registration: the Glaxo Wellcome experience. Int J Pharmaceut Med 2000;14:203–5
- Pharmaceutical Industry Clinical Trials Database. www.cmrinteract.com/clintrial/ [accessed 23 Sept 2003]
- Pharmaceutical Research & Manufacturers of America. Principles on conduct of clinical trials and communication of clinical trial results. http://www.phrma.org/publications/policy//2002-06-24.430.pdf [accessed 23 Sept 2003]